Drugs that contain Fludarabine Phosphate

1. Oforta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7547776 SANOFI AVENTIS US Process for the production of fludarabine-phosphate lithium, sodium, potassium, calcium and magnesium salts and purification process for the production of fludarabine-phosphate and fludarabine-phosphate with a purity of at least 99.5%
Dec, 2018

(5 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7148207 SANOFI AVENTIS US Oral fludara of high-purity formulation with quick release of active ingredient
Dec, 2022

(1 year, 4 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Dec 18, 2011
Orphan Drug Exclusivity(ODE) Dec 18, 2015

Market Authorisation Date: 18 December, 2008

Treatment: Treatment of patients with b-cell chronic lymphocytic leukemia (cll)


More Information on Dosage

OFORTA family patents

Family Patents